Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus UNIPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus UNIPEN IN PLASTIC CONTAINER.
AMPICILLIN TRIHYDRATE vs UNIPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic